1
2
3
4
5
6
7
8
9
10
11
12
13 | Licensing Program Analyst (LPA) Jessica Cho arrived unannounced for the purpose to investigate into the above allegation. LPA was greeted and allowed entry by Assistant Administrator (AA) Brian Nazareno. Licensee/Administrator (L/A) Rosario Nazareno arrived shortly after to assist LPA with the investigation. During today's visit, LPA obtained interviews with resident/staff and copies of pertinent facility/resident records that were reviewed on site. The following was revealed during the course of the investigation:
It is alleged that the facility is knowingly administering a medication that a resident is allergic to. While conducting a file review, Pencillin (PCN) is a known drug allergy for Resident #1 (R1) that was documented on two forms: Identification and Emergency Information (LIC601) dated January 2, 2023 and the Physician's Report dated April 18, 2023. Per the Medication Administration Record (MAR), LPA observed R1's allergies were not noted on the form. Augmentin, a derivative of PCN, was prescribed by the primary care physician and administered on October 12, 2023 and terminated on October 14, 2023 as noted on the MAR. Three out of the three staff confirmed the administration of Augmentin in |